Verily, Alphabet’s life sciences subsidiary, is undergoing a significant restructuring, leading to layoffs and the complete shutdown of its medical device program. CEO Stephen Gillet announced the changes in an internal memo, acknowledging the difficult decisions made to focus on precision health, data, and AI. While discontinuing device manufacturing, Verily will continue supporting existing innovations like the Dexcom G7. Post navigation Watch: Commuters flee as rocks fall in Arunachal; border route blocked by landslide Apple to announce new products at September 9 ‘Awe Dropping’ event
